Crysvita Եվրոպական Միություն - իսլանդերեն - EMA (European Medicines Agency)

crysvita

kyowa kirin holdings b.v. - burosumab - hypophosphatemia, familial; hypophosphatemic rickets, x-linked dominant; osteomalacia - lyf til að meðhöndla beinsjúkdóma - crysvita is indicated for the treatment of x-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. crysvita is indicated for the treatment of fgf23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.

Lupkynis Եվրոպական Միություն - իսլանդերեն - EMA (European Medicines Agency)

lupkynis

otsuka pharmaceutical netherlands b.v. - voclosporin - lupus nephritis - Ónæmisbælandi lyf - lupkynis is indicated in combination with mycophenolate mofetil for the treatment of adult patients with active class iii, iv or v (including mixed class iii/v and iv/v) lupus nephritis (ln).

Stamaril Stungulyfsstofn og leysir, dreifa Իսլանդիա - իսլանդերեն - LYFJASTOFNUN (Icelandic Medicines Agency)

stamaril stungulyfsstofn og leysir, dreifa

sanofi pasteur* - gulusóttarveira 17d-204 stofn (lifandi, veikluð) - stungulyfsstofn og leysir, dreifa

Bekemv Եվրոպական Միություն - իսլանդերեն - EMA (European Medicines Agency)

bekemv

amgen technology (ireland) uc - eculizumab - blóðrauði, ofsakláði - Ónæmisbælandi lyf - bekemv is indicated in adults and children for the treatment of paroxysmal nocturnal haemoglobinuria (pnh). sönnunargögn klínískum gagn er sýnt í sjúklinga með haemolysis með klínískum einkenni(s) marks um hár sjúkdómur starfsemi, óháð blóðgjöf sögu (sjá kafla 5.